8:00 - 8:10 am Welcome and Approval of 2016 Spring Meeting Minutes T. Petrella
8:10 - 8:40 am Results of CCSRI grant J. Dancey / T. Petrella
8:40 - 9:45 am Trial Updates

- MEC.3 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG) T. Petrella
- MEC.4 – Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma (Alliance) M. Butler
- MEC.5 – A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma (SWOG) T. Petrella
- IND224 – A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases T. Petrella
- IND225 – A Phase II Study of the Assessment of Response To Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker T. Petrella
- IND228 – A Phase II Study of Dervalumab and Tremelimumab in patients with advanced rare tumours J. Dancey
- ME13 – A Randomized Phase III Study of Duration of Anti-PD1 Therapy in Metastatic Melanoma (STOP-GAP) T. Petrella / Xinni Song
- PM1 – CANadian Profiling and Targeted agent Utilization Trial (CAPTUR). A phase II basket trial. J. Dancey
9:45 - 10:00 am Break

10:00 - 11:00 am New Proposals

- Prophylactic mesalamine to reduce immune-related AEs with combination ipilimumab / nivolumab in metastatic melanoma  J. Walker
- Immune signature study  J. Walker
- Intralesional IL-2 plus / minus Nivo for patients with stage IIIc, IVa melanoma  C. Giacomantonio
- Avelumab in metastatic SCC  T. Petrella
- S1616: Combining ipilimumab and nivolumab in advanced melanoma following progression on PD-1 inhibitor alone  T. Petrella
- Imaging follow Up in advanced, non-metastatic melanoma  S. Latosinsky

11:00 - 12:00 pm Genome Canada Grant  I. Watson/ A. Spatz

12:00 pm Meeting Adjourned

12:00 - 1:00 pm Executive Committee meeting to follow (closed)